RIGL
Rigel Pharmaceuticals, Inc.
39.83
4 x 38.83
1 x 39.91
bid
ask
+
1.54
4.02%
09:51 AM
timesize
Ytd-7.00%
1y113.57%
38.98
day range
39.94
18.24
52 week range
52.24
Open39.18Prev Close38.29Low38.98High39.94Mkt Cap737.12M
Vol44.44KAvg Vol394.00KEPS19.29P/E2.07Forward P/E19.49
Beta0.95Short Ratio1.69Inst. Own68.01%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0450-d Avg31.20200-d Avg34.011yr Est31.33

RIGL News

Rigel Appoints Board Member Alison L. Hannah, M.D.
prnewswire.com
Rigel Appoints Board Member Alison L. Hannah, M.D.

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Di

benzinga.com
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of J

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

benzinga.com
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and

These Analysts Increase Their Forecasts On Arvinas After Q1 Results
benzinga.com
These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
benzinga.com
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol

benzinga.com
Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel

Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted

benzinga.com
Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

benzinga.com
Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and

benzinga.com
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est

Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill

Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
benzinga.com
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

benzinga.com
Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the

Earnings Scheduled For May 5, 2026
benzinga.com
Earnings Scheduled For May 5, 2026

benzinga.com
Eli Lilly To Terminate Rigel Collaboration On RIPK1 Inhibitor Ocadusertib Effective June 15, 2026; D

 Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. (&#34

benzinga.com
FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Includ

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

benzinga.com
Rigel Pharmaceuticals Publishes Final Data From Phase 1/2 ARROW Trial Of Pralsetinib To Treat Metast

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hema

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Nasdaq Surges Over 1%; ISM Services PMI Tops Views
benzinga.com
Nasdaq Surges Over 1%; ISM Services PMI Tops Views

U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd

benzinga.com
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M

Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill

Earnings Summary: Rigel Pharmaceuticals Q4
benzinga.com
Earnings Summary: Rigel Pharmaceuticals Q4

benzinga.com
Rigel Pharmaceuticals Q4 Adj. EPS $1.12 Misses $1.25 Estimate, Sales $69.802M Beat $68.701M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.12 per share which missed the

Earnings Scheduled For March 3, 2026
benzinga.com
Earnings Scheduled For March 3, 2026

A Preview Of Rigel Pharmaceuticals's Earnings
benzinga.com
A Preview Of Rigel Pharmaceuticals's Earnings

benzinga.com
Rigel Reports Preliminary Q4 2025 Revenue Of $69.8M; Guides 2026 Revenue Of $275M-$290M

Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product

benzinga.com
Reported Sunday, Rigel Presents Updated Phase 1b R289 Data In Lower-Risk MDS At ASH 2025, Showing 33

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was ob

benzinga.com
Rigel Pharmaceuticals Reports Publication In The Journal Of Hematology & Oncology; 5-Year Data Showi

Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad ra

benzinga.com
Jefferies Upgrades Rigel Pharmaceuticals to Buy, Raises Price Target to $42

Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and rais

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Mov

benzinga.com
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $38

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neu

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
Rigel Pharmaceuticals Raises FY2025 Sales Guidance from $210.000M-$220.000M to $285.000M-$290.000M v

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 milli

benzinga.com
Rigel Pharmaceuticals Q3 EPS $1.46 Beats $0.84 Estimate, Sales $69.462M Beat $61.880M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the an

Earnings Scheduled For November 4, 2025
benzinga.com
Earnings Scheduled For November 4, 2025

benzinga.com
A Look Ahead: Rigel Pharmaceuticals's Earnings Forecast

benzinga.com
Rigel Pharma Announces First Patient Enrolled In Dose Expansion Phase Of Ongoing Phase 1b Study Of R

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusi

benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w

Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
benzinga.com
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday

benzinga.com
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $32

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neu

benzinga.com
Rigel Pharmaceuticals Q2 EPS $3.28 Beats $0.19 Estimate, Sales $101.685M Beat $48.142M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $3.28 per share which beat the an

benzinga.com
Rigel Pharmaceuticals Raises FY2025 Sales Guidance from $200.000M-$210.000M to $210.000M-$220.000M v

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $200.000 million-$210.000 milli

benzinga.com
Earnings Scheduled For August 5, 2025

benzinga.com
What to Expect from Rigel Pharmaceuticals's Earnings

benzinga.com
Rigel Pharmaceuticals To Present Final GAVRETO Phase 1/2 ARROW Study Data In RET Fusion-Positive NSC

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and ot

Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laborator

benzinga.com
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neu